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Background: Today’s standard treatment of advanced-stage ovarian cancer, including surgery followed by a
paclitaxel-platinum-based chemotherapy, is limited in efficacy. Recently, we could show that radioimmunotherapy
(RIT) with 177Lu-labelled anti-L1 cell adhesion molecule (L1CAM) monoclonal antibody chCE7 is effective in ovarian
cancer therapy. We investigated if the efficacy of anti-L1CAM RIT can be further improved by its combination with
paclitaxel (PTX).
Methods: In vitro cell viability and cell cycle arrest of human ovarian cancer cells were assessed upon different
treatment conditions. For therapy studies, nude mice (n = 8) were injected subcutaneously with IGROV1 human
ovarian carcinoma cells and received a single dose of 6 MBq 177Lu-DOTA-chCE7 alone or in combination with
600 μg PTX (31.6 mg/kg). Tumour growth delay and survival were determined. To investigate whether PTX can
influence the tumour uptake of the radioimmunoconjugates (RICs), a biodistribution study (n = 4) and SPECT/CT
images were acquired 120 h post injections of 2 MBq 177Lu-DOTA-chCE7 alone or in combination with 600 μg PTX.
Results: Lu-DOTA-chCE7 in combination with PTX revealed a significantly decreased cell viability of ovarian
carcinoma cells in vitro and was effective in a synergistic manner (combination index < 1). PTX increased the RIT
efficacy by arresting cells in the radiosensitive G2/M phase of the cell cycle 24 h post treatment start. In vivo
combination therapy including 177Lu-DOTA-chCE7 and PTX resulted in a significantly prolonged overall survival
(55 days vs. 18 days/PTX and 29 days/RIT), without weight loss and/or signs of toxicity. Biodistribution studies
revealed no significant difference in tumour uptakes of 177Lu-DOTA-chCE7 72 h post injection regardless of an
additional PTX administration.
Conclusions: Combination of anti-L1CAM 177Lu-RIT with PTX is a more effective therapy resulting in a prolonged
overall survival of human ovarian carcinoma-bearing nude mice compared with either monotherapy. The combination
is promising for future clinical applications.
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With an estimate of 21,980 new cases in the US alone,
ovarian carcinoma (OC) represents the fifth most com-
mon cause of cancer deaths in female population in 2014
[1]. Late diagnosis due to missing clinical symptoms or
diagnostic markers results in poor prognosis for patients
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reproduction in any medium, provided the origincluding widespread metastases at the time of diagnosis
[2,3]. Today’s front-line therapies, including surgery
followed by a paclitaxel-platinum treatment, fail to cure
late-stage OC. However, the 10-year survival rate is 40% to
50% with stage-related survival of 73% to 92% for stage I,
45% to 55% for stage II, 21% for stage III and less than 6%
for stage IV patients [3,4]. Therefore, alternative treatment
strategies are subject of intense research.
Besides conventional chemotherapy, numerous mono-
clonal antibodies (mAbs) have been developed for tar-
geted therapies for the future management of ovarianis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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ing results, clinical administration of mAbs as mono-
therapies or when combined with other treatment
modalities showed only limited clinical efficacy in OC
patients [6-9]. The reasons for restricted mAb activities
are not obvious. However, studies will benefit from larger
trials and appropriate patient selections to better define
the effectiveness of mAb-based therapies.
In order to improve the efficacy of mAb-based therap-
ies, radioimmunotherapy (RIT) is considered to be an at-
tractive strategy for the treatment of OC [10]. While
RIT has only a limited efficacy treating larger solid tu-
mours due to insufficient dose delivery, it is a suitable
therapy option for small-volume disseminated tumour
nodules that frequently occur after surgery of the pri-
mary tumours of the ovary [11,12]. However, only one
90Y-labelled radioimmunconjugate (90Y-muHMFG1) for
the treatment of OC has advanced to a clinical phase III
trial. Unfortunately, no improvement in extending sur-
vival or time to relapse could be achieved in particular
due to a missing dosimetric approach. Thereby, retro-
spective analysis revealed that tumour absorbed doses
had been too low [13,14].
The use of the high-energy-emitting radionuclide 90Y
and the application of a non-internalising antibody (anti-
MUC1) are considered further reasons for the limited
clinical outcome.
The L1 cell adhesion molecule (L1CAM) was origin-
ally described as a protein of the nervous system and is
highly expressed on numerous tumours such as neuro-
blastoma [15], colon carcinoma [16], melanoma [17],
pancreatic adenocarcinoma [18] and ovarian carcinoma
[19]. Its expression in cancer is correlated with increased
cell proliferation, migration, angiogenesis as well as
apoptosis protection [15,19,20]. Therefore, L1CAM is a
promising target for novel therapies [21-24].
chCE7 is a chimeric monoclonal antibody that is di-
rected against the L1CAM cell surface antigen. mAb
chCE7 binds with high affinity (KD ≈ 10
−10 mol/l) near
an RGD sequence in the sixth IgG-like domain of
L1CAM, inhibiting tumour cell growth in vitro and
in vivo [15,25,26]. The antibody-antigen complex inter-
nalises into the targeted cell through endocytosis. We
demonstrated that a 177Lu-labelled variant of mAb
chCE7 showed high efficacy in a xenograft model of dis-
seminated ovarian carcinoma [25].
Preclinical studies have demonstrated that combined
treatments including RIT and radiosensitising taxanes
such as paclitaxel (PTX) can be advantageous compared
to monotherapies [27-29]. PTX belongs to the group of
microtubule-stabilising agents and induces apoptosis
and arrest of tumour cells in the radiosensitive G2/M
phase of the cell cycle based on suppression of micro-
tubule dynamics. Furthermore, it was shown that PTXinfluences the tumour microenvironment, resulting in
reoxygenation of the tumour potentially providing radio-
sensitising effects [30,31].
In this study, we investigated whether the efficacy of
previously developed anti-L1CAM 177Lu-RIT against ovar-
ian carcinoma can be further increased by its combination
with the radiosensitising taxane PTX.
Methods
Cell culture and antibody formats
IGROV1 human ovarian cancer cells were kindly provided
by Dr. Cristina Müller (Center for Radiopharmaceutical
Sciences, Paul Scherrer Institute) and analysed by STR
profiling (DSMZ, Braunschweig, Germany). IGROV1 cells
were maintained in a humidified atmosphere containing
5% CO2 in RPMI 1640 medium at 37°C. The medium was
supplemented with 10% fetal calf serum (FCS), 2 mM
glutamine, 100 units/ml penicillin, 100 μg/ml strepto-
mycin and 0.25 μg/ml fungizone (BioConcept, Allschwil,
Switzerland). mAb chCE7 is a IgG1-subtype chimeric
monoclonal antibody (human κ light chain and human γ1
heavy chain). It was produced in HEK293 cells and purified
from cell culture supernatant using a protein G-Sepharose
column (GE Healthcare, Glattbrugg, Switzerland) as de-
scribed by Grünberg et al. [32]. An unspecific isotype-
matched IgG was used as a control for experiments.
Ligand substitution and antibody radiolabelling
Ligand substitution was performed as previously de-
scribed by Fischer et al. [25]. For ligand conjugation, the
molar excess of p-SCN-Bn-DOTA (Macrocyclics, Dallas,
TX, USA) was adapted individually for each antibody to
achieve similar DOTA ligands to mAb ratios. The reaction
mixture was adjusted to pH 9 to 10 using a saturated
Na3PO4 solution and was incubated for 16 h at 4°C. Excess
ligands were removed and buffer was exchanged into
0.25 M CH3COONH4 (pH 5.5) using a NAP-5 column
(GE Healthcare, Glattbrugg, Switzerland). Immunoconju-
gates were stored at −80°C.
The average number of coupled chelators per mAb
was determined by mass spectrometry as previously de-
scribed [25]. 177Lu (ITG, Garching, Germany) was uti-
lised for radiolabelling 1 to 3 days post calibration date.
Briefly, a reaction mixture containing 250 to 900 μg of
the immunoconjugates and 200 to 600 MBq 177Lu was
incubated in 0.25 M CH3COONH4 buffer (pH 5.5) for
1 h at 37°C.
After incubation, EDTA was added to a final concen-
tration of 5 mM for 5 min in order to complex free
lutetium. Radioimmunoconjugates (RICs) were purified
via FPLC size exclusion chromatography on a Superose
12 column (GE Healthcare, Glattbrugg, Switzerland) in
phosphate-buffered saline (PBS) with a flow rate of
0.5 ml/min. Both radiolabelled chCE7 and unspecific
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order to test the stability of 177Lu-labelled antibodies,
RICs were incubated in human plasma at 37°C and ana-
lysed by FPLC size exclusion chromatography on a
TSKgel G3000Wxl column (Tosoh Bioscience, Stuttgart,
Germany). The flow rate of the mobile phase (0.3 M
NaCl, 0.05 M Na2HPO4, pH 6.2) was set to 1 ml/min
(Additional file 1: Figure S1).
FACS cell cycle analysis upon PTX treatment
For cell cycle analysis, IGROV1 cells were seeded in a
six-well plate (0.75 × 105/well) and incubated for 24 h.
The medium was removed and cells were incubated with
the accordant ½ half-maximal inhibitory concentration
(½ IC50, 5 nM) or IC50 (10 nM) of PTX for 24 h at 37°C.
PTX ½ IC50 was calculated based on the experimentally
determined IC50 value using a 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability
assay (Additional file 1: Figure S2). Afterwards, cells
were washed with PBS, detached and fixed in 70% etha-
nol (24 h, −20°C). After additional washing with PBS,
cells were incubated with 0.5 μg/ml propidium iodide
(PI) solution (Sigma-Aldrich, Buchs, Switzerland) for
40 min at room temperature (RT) and analysed by flow
cytometry. All results were evaluated with FlowJo soft-
ware (Tree Star, Ashland, OR, USA, version 10).
In vitro cell viability assay
In order to determine the 177Lu-DOTA-chCE7 concen-
trations necessary to reduce cell viability to 50% (IC50),
IGROV1 cells were seeded in a 96-well plate and incu-
bated for 24 h at 37°C. After adhesion, cells receiving
combination treatment were incubated with the accord-
ant ½ IC50 (5 nM) or IC50 (10 nM) PTX concentrations
for 24 h at 37°C in order to maximise the amount of
cells being arrested in the G2/M phase of the cell cycle.
Cells were then washed with PBS and treated with
100 μl (0.02 to 42 MBq/ml) 177Lu-DOTA-chCE7 for 4 h
on ice. Subsequently, cells were washed and incubated
in culture medium at 37°C. Cell viability was determined
when 20 μl of filtered MTT solution (5 mg/ml, Sigma-
Aldrich) was added to each well followed by incubation
for 2 h protected from light. The medium was removed
and the formed formazan crystals were dissolved in
200 μl dimethyl sulfoxide (DMSO). The absorbance
(OD) was determined at a wavelength of 560 nm in a
microplate reader (Victor X3, PerkinElmer, Waltham,
MA, USA). Results are expressed as percentage of viable
cells compared to the control.
In vivo therapy studies
All animal experiments were approved by the cantonal
committee on animal experiments and permitted by the
responsible cantonal authorities (permission numbers75528 and 75535). The studies were conducted in com-
pliance with the Swiss laws on animal protection. For
survival studies, groups of eight female CD1 nude mice
(Charles River, Sulzfeld, Germany, 5 weeks old) were
injected subcutaneously (s.c.) with 7 × 106 IGROV1
cells (100 μl, in sterile PBS) into the right flank. Eight
days post tumour cell inoculation, therapy experiments
started (mean tumour volume = 60 ± 30 mm3). Mice
were injected with a) 6 MBq (50% maximum tolerated
activity (MTA), 25 μg, 100 μl) 177Lu-DOTA-chCE7, b)
6 MBq 177Lu-DOTA-control IgG (25 μg, 100 μl) or c)
PBS into the tail vein. MTA of 177Lu-DOTA-chCE7 was
determined elsewhere [33]. Twenty-four hours later,
groups that should receive the combination therapy or
PTX alone were injected intraperitoneally (i.p.) with 600 μg
PTX (31.6 mg/kg, clinical formulation; Taxol, Bristol-Myers
Squibb, Zürich, Switzerland, 1:3 dilution with PBS; 300 μl).
Since the maximum tumour uptake of 177Lu-DOTA-chCE7
is reached at 48 to 72 h after injection of RIC (i.v.), PTX
was administered 24 h post RIT in order to synchronise the
maximum tumour uptake of the radiolabeled mAb and
PTX-induced cell cycle arrest in the G2/M phase.
Concentration was chosen based on previous experi-
ments determining 600 μg/mouse as a reliable dosage for
PTX administration in combination with RIT [34,35].
Animals were examined two to three times a week and
weighed, and tumour volumes were measured with V =
(A × B2)/2, where A is the smaller diameter and B the
wider diameter of the tumour. The relative tumour vol-
ume (RTV) was calculated with Vx/V0 (Vx = tumour vol-
ume at given time, V0 = tumour volume at therapy
starting point). Relative body weight (RBW) was measured
with Wx/W0 (Wx = body weight at given time, W0 = body
weight at therapy starting point). Animals were eutha-
nised if the tumour volume exceeded 1,000 mm3 or ob-
served weight loss was greater than 20%. In order to
avoid bias in the test results, treatment information
was blinded to the tester during the course of the
therapy.
Biodistribution studies
For biodistribution studies, groups of four female CD1
nude mice (Charles River, Sulzfeld, Germany) were
injected s.c. with 7 × 106 IGROV1 cells at the age of
5 weeks. Fourteen days post tumour cell inoculation,
0.85 MBq (25 μg, 100 μl) 177Lu-DOTA-chCE7 was
injected into the tail vein. Twenty-four hours later, mice
received either 600 μg PTX (31.6 mg/kg, clinical formu-
lation; Taxol, Bristol-Myers Squibb, Zürich, Switzerland,
1:3 dilution with PBS; 300 μl) i.p. or 300 μl PBS i.p. Con-
trol mice were injected with 0.85 MBq 177Lu-DOTA-
control IgG (25 μg, 100 μl). Mice were sacrificed 72 h
post RIC administration, and organs as well as tumours
were weighed and counted for radioactivity in a gamma
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USA). Results are expressed as percentage of the injected
activity per gram of tissue weight (%IA/g).SPECT/CT imaging studies
SPECT/CT imaging studies were performed in a
NanoSPECT/CT system (Bioscan, Washington, DC,
USA). 177Lu-DOTA-chCE7 (6 MBq, 25 μg, 100 μl) was
injected into the tail vein of tumour-bearing nude mice
24 h prior to i.p. administration of 600 μg (31.6 mg/kg)
PTX or PBS. Control mice received 177Lu-DOTA-con-
trol IgG. SPECT/CT scans were performed 96 h
(177Lu-DOTA-control IgG) and 120 h (177Lu-DOTA-
chCE7, 177Lu-DOTA-chCE7 + PTX) after RIC administra-
tion. SPECT data were reconstructed by HighSPECT soft-
ware (ver. 1.4.3049, Scivis). Reconstruction of CT data,
fusion with SPECT data and analysis were performed by
InVivoScope postprocessing software (ver. 1.44, Bioscan,
Washington, DC, USA).Statistical analysis
Statistical analysis of the survival experiment was per-
formed via a log-rank test. Bonferroni correction was
used to determine statistical significance for multiple
comparisons. Significance was defined as p < 0.0083.
Student’s t test (unpaired, two-tailed) was used for com-
parison of tumour volumes and biodistribution experi-
ments. Statistical significance was defined as p < 0.05. In
vitro data was analysed via combination index calculations
(CI = (CA,x/Icx,A) + (CB,x/Icx,B)). Thereby, concentrations
required to produce a given effect are determined for drug
A (Icx,A) and drug B (Icx,B). CA,x and CB,x are the concen-
trations of A and B contained in combination that provide
the same effect. Synergy is determined for CI < 1, additivity




































Figure 1 FACS analysis of PTX pre-treated IGROV1 cells. (a) Untreated
5 nM PTX (½ IC50) for 24 h at 37°C.Results
Ligand substitution and antibody radiolabelling
Mass spectroscopic analysis of the DOTA-to-mAb ratios
for mAb chCE7 and the control IgG revealed that an
average of 2.7 to 3.1 (chCE7) or 3.1 (control IgG) chelators
were coupled to an intact antibody molecule. Specific
activity obtained upon 177Lu labelling was 240 to 600 MBq/
mg protein. Immunoreactivity was proven by the Lindmo
method (50% to 87%).
PTX treatment induces G2/M phase arrest
Figure 1 shows fluorescence-activated cell sorting (FACS)
analysis histograms after IGROV1 cells have been treated
with ½ IC50 (5 nM) or IC50 (10 nM) PTX concentrations
for 24 h. An increased amount of IGROV1 cells arrested
in the G2/M phase of the cell cycle could be observed for
cells treated with 10 nM PTX (46.5% ± 3.4%, Figure 1b)
compared to untreated control cells (25.2% ± 7.3%,
Figure 1a). Furthermore, an increased sub-G1 popula-
tion (18.2% ± 2.2%, Figure 1b) was detected during
PTX treatment. Thereby, G0/G1 population decreased
from 54.5% ± 2.5% (untreated cells) to 15.7% ± 1.2%.
The treatment with 5 nM PTX resulted in 17.0% ±
9.3% cells being arrested in the G2/M phase of the cell
cycle accompanied by an increased sub-G1 population
(25.4% ± 4.8%, Figure 1c) compared to the control. The
G0/G1 cell population decreased to 36.7% ± 13.6%
compared to the untreated cells.
In vitro cell growth inhibition upon 177Lu-DOTA-chCE7
and paclitaxel treatments
In order to investigate whether PTX can sensitise IGROV1
cells towards subsequent 177Lu-DOTA-chCE7 treatment,
cell growth inhibition upon single or combined treatments
was examined by MTT proliferation assays using previ-
ously determined IC50 (10.0 ± 1.0 nM) and ½ IC50 (5 nM)
















control, (b) incubated with 10 nM PTX (IC50) or (c) incubated with
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mined IC50 (Additional file 1: Figure S2). Treatment of
IGROV1 cells with 177Lu-DOTA-chCE7 alone revealed an
IC50 of 11.9 ± 1.9 MBq/ml (Figure 2). Combined treatment
including PTX and 177Lu-DOTA-chCE7 resulted in
decreased IC50 values of 3.5 ± 1.3 MBq/ml (
177Lu-DOTA-
chCE7 + 5 nM PTX) and 2.9 ± 1.2 MBq/ml (177Lu-DOTA-
chCE7 + 10 nM PTX). In order to determine synergistic or
additive effects, combination index (CI) calculations as pub-
lished by Zhao et al. were used [36]. For a cell growth in-
hibition of 50%, the additional application of PTX (½ IC50)
increases the cytotoxic effect of 177Lu-DOTA-chCE7 in a
synergistic manner (CI < 1). In order to provide additional
information about the long-term colony-forming ability of
IGROV1 cells after mono- (177Lu-DOTA-chCE7) or com-
bined (PTX+ 177Lu-DOTA-chCE7) treatments, colony as-
says were assessed. Results indicate that the cytotoxicity of
177Lu-DOTA-chCE7 can be increased by the additional ap-
plication of paclitaxel (½ IC50) 24 h prior to RIT (Additional
file 1: Figure S3). Thereby, IC50 values decreased from
1.5 MBq/ml (177Lu-DOTA-chCE7) to 0.75 MBq/ml for
combined treatment (PTX+ 177Lu-DOTA-chCE7). Simul-
taneous administration or application of PTX 16 h after
177Lu-DOTA-chCE7 did not increase the cytotoxicity ef-
fects of RIT necessary for 50% cell growth inhibition.
Combination of 177Lu-DOTA-chCE7 and PTX results in
prolonged survival of human ovarian carcinoma-bearing
nude mice
To investigate whether a combined treatment of 177Lu-
DOTA-chCE7 and PTX results in delayed tumour growthFigure 2 In vitro effects of single or combination treatments
containing 177Lu-DOTA-chCE7 and PTX on IGROV1 cell viability.
Determination of cell growth was assessed via MTT assays 120 h post
treatment. Results are expressed as percentage of an untreated control.and prolonged survival compared to monotreatments,
a therapy experiment was performed in nude mice.
Xenografts were generated by s.c. injection of IGROV1
human ovarian carcinoma cells into female CD1 nude
mice.
Eight days post implantation of tumour cells, mice re-
ceived an i.v. injection of 6 MBq 177Lu-DOTA-chCE7
(25 μg) followed by 600 μg PTX 24 h later. Control mice
received either 6 MBq (25 μg) of a 177Lu-labelled unspe-
cific control IgG or PBS. Mice were monitored two to
three times a week with end point criteria set as weight
loss >20% or increased tumour volume >1,000 mm3.
Average RTVs, average RBWs and Kaplan-Meier survival
plots were recorded. Tumour growth curves were
stopped at the exclusion day of the first mouse in each
group. Untreated control mice showed a fast increase in
tumour volume from the beginning of the therapy
experiment, indicating an uninhibited tumour growth
(Figure 3a). The group that received the combination
therapy (177Lu-DOTA-chCE7 + PTX) demonstrated the
most pronounced delay in tumour growth. The mean
RTV < 1 between days 4 and 18 post treatment start in-
dicates tumour shrinkage. Complete tumour clearance
or shrinkage below detection limits was observed in
seven out of eight mice until day 13. During this time, a
reduced tumour burden with a significant decrease in
average RTV on day 13 was observable for mice treated
with anti-L1CAM combination therapy compared to all
other treatment groups (vs. 177Lu-DOTA-chCE7: p < 0.05;
vs. PTX: p < 0.05; vs. 177Lu-DOTA-control IgG + PTX:
p < 0.05). Additionally, no weight loss >20% or signs of
distress could be observed at any time during the therapy
experiment. Combination of 177Lu-DOTA-chCE7 and PTX
resulted in a significantly prolonged overall survival
compared to mice that received only 177Lu-RIT or PTX
(vs. 177Lu-DOTA-chCE7: p = 0.0013; vs. PTX: p = 0.0002;
Figure 3b). Thereby, median survival was increased from
18 days (PTX) and 29 days (177Lu-DOTA-chCE7) up to
55 days for the combination therapy. Additionally, a sig-
nificantly prolonged survival could be shown for mice re-
ceiving anti-L1CAM combination therapy compared to
untreated controls (PBS) and mice that received unspecific
treatments (vs. PBS: p = 0.0001; vs. 177Lu-DOTA-control
IgG: p = 0.0001; vs. 177Lu-DOTA-control IgG + PTX:
p = 0.0002). No significant difference in overall survival
could be observed between PTX monotreatment and
the untreated control (p = 0.29).
The 177Lu-RIT alone increased overall survival signifi-
cantly compared to mice that received only PBS (p =
0.0017). A regular increase in mean RBW for mice that
received the combination of 177Lu-DOTA-chCE7 and
PTX could be observed until day 37 post treatment start
indicating no therapy-induced weight loss and/or signs
of toxicity (Figure 3c). However, subsequent decrease in
Figure 3 Therapeutic efficacy of anti-L1CAM RIT in combination with PTX. Tumour-bearing nude mice (n = 8) received 177Lu-DOTA-chCE7
(6 MBq, 50% MTA, i.v.) followed by PTX (600 μg, i.p.) 24 h later for combination therapies. Control mice received PBS, PTX or 6 MBq (25 μg) of
177Lu-labelled unspecific control IgG with or without PTX. (a) Mean relative tumour volume ± SD. Tumour growth curves were stopped when the
first tumour in a treatment group reached 1,000 mm3. (b) Kaplan-Meier plots of the therapy experiment. (c) Development of body weight during
therapy. Mean relative body weight ± SD.
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tumour burden.
Comparative biodistributions and SPECT/CT imaging post
177Lu-DOTA-chCE7 and PTX administrations
Previously, Jang et al. [27] investigated the effect of PTX
on the efficacy of 90Y-labelled B3 mAb in Ley antigen-
positive A-431 human epidermoid carcinoma xenografts.
It was demonstrated that PTX significantly increased the
accumulation and penetration of mAb B3 into the
tumour microenvironment compared to the control,
supporting synergistic effects of the combined therapy.
In order to investigate whether PTX treatment influ-
ences the biodistribution of 177Lu-DOTA-chCE7, female
CD1 nude mice (n = 4) were injected i.v. with 0.85 MBq177Lu-DOTA-chCE7 14 days post s.c. implantation of
IGROV1 tumour cells. Twenty-four hours post 177Lu-
DOTA-chCE7 administration, one group of mice addition-
ally received 600 μg PTX (i.p.). Control mice (n = 5) were
injected with a non-binding 177Lu-DOTA-control IgG with
or without PTX treatment. Accumulated radioactivity in
tumour tissue was high after 72 h (49.6% ± 11.9%) for mice
injected with 177Lu-DOTA-chCE7 compared to reasonably
low uptakes for all non-targeted organs and the blood pool
(<9%; Table 1). RIC uptake of 45.3% (±8.6%) per gram
tumour tissue could be reached in mice that received
successive 177Lu-DOTA-chCE7 and PTX administrations.
Accumulated radioactivity in tumours did not differ signifi-
cantly for both groups (p = 0.58), implying that PTX has no
effect on the tumour uptake of 177Lu-DOTA-chCE7.
Table 1 Biodistribution of 177Lu-DOTA-chCE7 and 177Lu-DOTA-control IgG 72 h post RIC injection in nude mice bearing
subcutaneous IGROV1 tumours (±PTX)
Organs 177Lu-DOTA-chCE7 177Lu-DOTA-chCE7 + PTX 177Lu-DOTA-control IgG 177Lu-DOTA-control IgG + PTX
Blood 8.9 ± 2.8 6.9 ± 3.5 17.12 ± 3.6 13.3 ± 8.5
Heart 3.9 ± 0.8 3.3 ± 1.4 5.7 ± 2.9 3.9 ± 1.7
Spleen 7.0 ± 2.3 5.7 ± 1.0 5.0 ± 2.8 10.2 ± 6.1
Kidney 2.8 ± 0.3 2.4 ± 0.6 5.4 ± 1.9 4.6 ± 1.8
Stomach 0.4 ± 0.2 0.4 ± 0.1 0.8 ± 0.8 1.0 ± 0.4
Intestine 0.8 ± 0.2 0.7 ± 0.3 1.1 ± 0.3 0.4 ± 0.5
Liver 5.3 ± 1.8 5.7 ± 0.3 5.7 ± 2.5 6.7 ± 1.2
Muscle 0.9 ± 0.2 0.8 ± 0.2 1.1 ± 0.3 1.4 ± 0.6
Bone 1.5 ± 0.2 1.1 ± 0.5 1.9 ± 0.6 2.6 ± 0.5
Tumour 49.6 ± 11.9 45.3 ± 8.6 7.2 ± 2.3 9.1 ± 3.1
Results shown in %IA/g ± SD.
Lindenblatt et al. EJNMMI Research 2014, 4:54 Page 7 of 10
http://www.ejnmmires.com/content/4/1/54Similarly, PTX had no influence on the accumulation of
177Lu-DOTA-chCE7 in all other organs and the blood pool.
As expected, the tumour uptake of the 177Lu-DOTA-con-
trol IgG was low regardless of a following PTX administra-
tion. For 177Lu-DOTA-control IgG, we observed a longer
retention time in the blood pool compared to 177Lu-
DOTA-chCE7. Very low radioactivity in the bones indi-
cates maintained stability of the 177Lu-DOTA complex
after 72 h post injection. We further analysed the distribu-
tion of 177Lu-DOTA-chCE7 in subcutaneous IGROV1
tumour-bearing nude mice at 120 h post RIC administra-
tion via SPECT/CT. Injection of 177Lu-DOTA-chCE7
(Figure 4a) and combined administrations of 177Lu-
DOTA-chCE7 and PTX (Figure 4b) show similar high up-
takes of the RICs in the tumours located at the right
shoulder. In both cases, almost no remaining activity in
other non-targeted organs could be observed, matching
the low accumulation percentages obtained from biodistri-
bution studies of the earlier time point (72 h). Addition-
ally, SPECT/CT images indicate that 177Lu-DOTA-chCE7
was equally distributed throughout the tumour regardless
of a following PTX injection. Neither an uptake at the site
of tumour implantation nor uptake in other organs could
be detected 96 h post injection of 177Lu-DOTA-control
IgG (Figure 4c).Discussion
We have previously demonstrated that anti-L1CAM RIT
using the mAb chCE7 is effective against small dissemi-
nated ovarian tumour nodules in a preclinical setting
[25,37]. In this study, we asked for the first time if the
efficacy of L1CAM-targeted ovarian cancer RIT can be
further improved by the introduction of PTX into the
therapy scheme. Therefore, the efficacies of 177Lu-
DOTA-chCE7 and PTX monotreatments were com-
pared to the combined treatment modality. We furtherevaluated if PTX influences the tumour uptake of 177Lu-
DOTA-chCE7.
After adding PTX at IC50 to IGROV1 ovarian cancer
cells, the number of cells being arrested in the radiosen-
sitive G2/M phase of the cell cycle could be increased at
24 h after treatment start. In contrast, PTX at ½ IC50
showed no increase in G2/M phase arrested cells com-
pared to an untreated control, suggesting that the ap-
plied concentration was not sufficient to induce cell
cycle arrest. Nevertheless, for both concentrations, the
appearance of sub-G1 populations was demonstrated.
These results agree with previous observations that
low PTX concentrations (<10 nM) induced an increased
amount of apoptosis without evidence for existent G2/M
arrest compared to a control. This effect might be
caused by the fact that lower PTX concentrations (<10
nM) do not completely saturate PTX binding sites in a
part of the cell population, which in turn leads to pro-
gression of the cell cycle, chromosomal instability and
induction of apoptosis [38]. For intermediate PTX con-
centrations (≥10 nM), saturation of microtubule binding
sites may be further increased, leading to G2/M arrest
and apoptosis [38]. However, in both cases, 177Lu-
DOTA-chCE7 concentrations necessary to reduce cell
viability to 50% of untreated controls could be reduced
3.2-fold by combination with low-dose PTX at ½ IC50 or
4.3-fold when combined with IC50 PTX intermediate
dosages. For 50% cell growth inhibition, combination
index calculations revealed that monotreatments (½ IC50
PTX + 177Lu-DOTA-chCE7) were combined in a syner-
gistic manner.
Increased therapeutic efficacy of RIT upon combination
with PTX has been previously shown by Jang et al. [27]
when anti-Ley 90Y-labelled mAb B3 and PTX combination
therapy resulted in a significantly prolonged survival of
human epidermoid carcinoma-bearing mice. Milenic et al.
[34] demonstrated an increased therapeutic efficacy when
Figure 4 Whole-body SPECT/CT images of IGROV1 xenografts. CD1 nude mice were injected i.v. with 6 MBq of (a) 177Lu-DOTA-chCE7 or
(b) 177Lu-DOTA-chCE7 and 600 μg PTX 24 h post RIC administration or (c) 177Lu-DOTA-control IgG. Images were taken 120 h post RIC injection
(control 96 h).
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was combined with PTX in a human colon carcinoma
tumour model. However, the radioisotope 177Lu is a more
suitable candidate for RIT against smaller tumours that
frequently appear in ovarian cancer. 177Lu shows an in-
creased half-life of 6.7 days compared to 213Bi (45 min),
thereby matching the slow pharmacokinetics of IgGs when
injected intravenously. Furthermore, an intravenous appli-
cation of the RIC might have advantages in terms of tar-
geting distant metastasis beyond the peritoneal cavity.
Thereby, 177Lu lower tissue penetration range (≈2 mm) is
likely to be superior to 90Y in the treatment of small dis-
seminated ovarian cancer tumour nodules [25]. Our ani-
mal studies demonstrated that combined application of
PTX and anti-L1CAM 177Lu-DOTA-chCE7 led to an in-
creased therapeutic efficacy in a xenograft model, resulting
in a significantly prolonged overall survival. Thereby, PTX
was administered 24 h post RIT in order to adapt peak
concentrations of 177Lu-DOTA-chCE7 and PTX in the
tumour. Results indicate that PTX has the ability to in-
crease the cytotoxic effects on IGROV1 tumour cells in-
duced by 177Lu-DOTA-chCE7. Mice that received only
PTX monotreatment showed no significant difference in
tumour growth delay and overall survival compared tountreated control mice, implying that only subcytotoxic
PTX concentrations (600 μg, 31.6 mg/kg) were used. Ob-
servation of insignificant tumour suppression of PTX
monotreatments compared to untreated controls is in line
with previous studies demonstrating the limited subthera-
peutic effect of low-dose PTX treatments [35].
Biodistribution studies demonstrated high tumour up-
takes for the specific RIC correlating with low remaining
levels of activity in the blood pool 72 h post RIC injec-
tion, regardless of an additional PTX administration.
Thus, PTX did not influence the 177Lu-DOTA-chCE7
uptake in either way. As expected, tumour uptake of the
control RIC with or without PTX application was very low,
indicating only a non-specific accumulation. Low non-
specific tumour uptakes were consequently accompanied
by higher remaining levels of activity in the blood pool.
Jang et al. [27] demonstrated that higher PTX dosages
(>600 μg) as well as larger mean tumour volumes at
therapy start (≈200 mm3) showed decreased interstitial
fluid pressure and increased blood vessel permeability
resulting in higher RIC accumulation in the tumour. In
our studies, increased tumour accumulation was not ob-
served, supporting our assumption that cell cycle arrest
in the G2/M phase played a major role during in vivo
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tumour microenvironment caused by PTX cannot be fully
excluded, since cellular and tumour microenvironmental
effects are known to complement each other [31].
Even though the therapeutic efficacy of 177Lu-DOTA-
chCE7 was increased by the introduction of PTX into the
treatment scheme, no weight loss or a decreasing number
of white blood cells was induced (data not shown).
While the application of a third chemotherapeutic is
thought to result in unjustifiable toxicities for patients,
RIT has shown to be well tolerated with low toxicity
levels. Therefore, RIT/paclitaxel/platinum-based chemo-
therapy combination offers an alternative treatment
strategy that may improve the efficacy of a first-line
platinum-paclitaxel treatment. Nevertheless, such an alter-
native treatment strategy has to be verified in large, rando-
mised clinical trials. Since patterns of platinum resistance
and mechanisms of action for microtubule-stabilising
agents do not necessarily interact, patients with platinum-
refractory, platinum-resistant disease or platinum-resistant
relapse might benefit from a RIT/paclitaxel combination.
Again, this has to be verified in clinical trials.
Malignant ascites are frequently occurring in patients
with advanced ovarian cancer with only limited treat-
ment options. So far, catumaxomab, a trifunctional
mAb, is used for the effective treatment of EpCAM-
positive tumour cells in the peritoneal cavity [39]. An ef-
fective treatment against L1CAM-positive tumour cells
in the peritoneal cavity might therefore decrease the
amount of free tumour cells (spheroids) potentially redu-
cing the burden of occurring ascites.Conclusions
It is well known that patients suffer from severe side ef-
fects (e.g. neuropathy and myelosuppression) induced by
high concentrations of PTX during treatment cycles [40].
Since RIT is more tolerable compared to high-dosage che-
motherapies, a combination with radiosensitising agents
like PTX might result in a similar or better therapeutic
outcome, while lower effective therapeutic PTX dosages
are necessary compared to mono-chemotherapeutic treat-
ments. The introduction of PTX in the therapy scheme of
L1CAM-targeted 177Lu-DOTA-chCE7 RIT may provide a
potential clinical setup against residual ovarian tumour
nodules after first-line tumour resection. Patients may
therefore benefit from decreased side effects during ther-
apy and possible increased therapeutic efficacy.Additional file
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